The dual FAK-HDAC inhibitor MY-1259 displays potent activities in gastric cancers in vitro and in vivo

[Display omitted] •Dual inhibitor of focal adhesion kinase (FAK) and histone deacetylases 6 (HDAC6) was first reported.•MY-1259 exhibited potent inhibitory activities in gastric cancer cells.•MY-1259 displayed highly potent activities against FAK and HDAC6.•MY-1259 was superior in the inhibition of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Bioorganic chemistry 2023-02, Vol.131, p.106328-106328, Article 106328
Hauptverfasser: Song, Jian, Liu, Xu, Zhang, Yi-Fan, Tian, Xin-Yi, Deng, Meng-Yan, Huang, Chen-Zheng, Zhang, Sai-Yang
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:[Display omitted] •Dual inhibitor of focal adhesion kinase (FAK) and histone deacetylases 6 (HDAC6) was first reported.•MY-1259 exhibited potent inhibitory activities in gastric cancer cells.•MY-1259 displayed highly potent activities against FAK and HDAC6.•MY-1259 was superior in the inhibition of in gastric cancer cells MGC-803 Xenograft Model than that of SAHA and TAE-226, either alone or and in combination. Epigenetic regulation and Focal adhesion kinase (FAK) are considered to be two important targets for the development of antitumor drugs. Studies have shown that the combination of FAK and HDAC inhibitors could exhibit synergistic effects in a subset of cancer cells in vitro and in vivo. At present, there are few reports on dual target inhibitors of FAK and HDAC. Here, we first reported a new compound MY-1259 as a dual FAK and HDAC6 inhibitor, which exhibited efficient treatment effects on gastric cancers in vitro and in vivo. MY-1259 exhibited potent inhibitory activities against FAK (IC50 = 132 nM) and HDAC6 (IC50 = 16 nM). Notably, MY-1259 showed selective inhibitory potency on HDAC6 over HDAC1, HDAC2 and HDAC3. In addition, MY-1259 could potently inhibit the proliferative activities of MGC-803 and BGC-823 cells (IC50 = 3.91 and 15.46 nM, respectively, using flow cytometry counting), induce cell apoptosis, and cellular senescence. MY-1259 could effectively down-regulate the levels of Ac-Histone H3 and Ac-α-tubulin, and also inhibit the phosphorylation of FAK at three phosphorylation sites Y397, Y576/577 and Y925, thereby inhibiting the activation of ERK and AKT/mTOR. MY-1259 exhibited more effective antitumor effect in vivo than the HDAC inhibitor SAHA and FAK inhibitor TAE-226 alone or in combination, showing the advantages of FAK/HDAC dual inhibitors in the treatment of gastric cancers. Therefore, the results in this work suggested that inhibition of FAK and HDAC by MY-1259 might represent a promising strategy for the treatment of gastric cancers.
ISSN:0045-2068
1090-2120
DOI:10.1016/j.bioorg.2022.106328